# Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine 

Anssi Nurminen ${ }^{1}$, Serafina Jaatinen ${ }^{1}$, Sinja Taavitsainen ${ }^{1}$, Gunilla Högnäs ${ }^{1}$, Tom Lesluyes ${ }^{2}$, Naser Ansari-Pour ${ }^{3}$, Teemu Tolonen ${ }^{4}$, Kerstin Haase ${ }^{2,5}$, Antti Koskenalho ${ }^{1}$, Matti Kankainen ${ }^{6}$, Juho Jasu ${ }^{1}$, Hanna Rauhala ${ }^{1}$, Jenni Kesäniemi ${ }^{1}$, Tiia Nikupaavola ${ }^{1}$, Paula Kujala ${ }^{4}$, Irina Rinta-Kiikka ${ }^{7}$, Jarno Riikonen ${ }^{8}$, Antti Kaipia ${ }^{8}$, Teemu Murtola ${ }^{1,8}$, Teuvo L. Tammela ${ }^{1,8}$, Tapio Visakorpi ${ }^{1,4}$, Matti Nykter ${ }^{1}$, David C. Wedge ${ }^{9}$, Peter Van Loo ${ }^{2,10,11}$ and G. Steven Bova ${ }^{1 *}$ ©


#### Abstract

Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as an essential feature. Whether or not analysis of genomic data in an evolutionary context in primary prostate cancer can provide unique added value in the research and clinical domains remains an open question. Methods We used novel processing techniques to obtain whole genome data together with 3D anatomic and histomorphologic analysis in two men (GP5 and GP12) with high-risk PrCa undergoing radical prostatectomy. A total of 22 whole genome-sequenced sites ( 16 primary cancer foci and 6 lymph node metastatic) were analyzed using evolutionary reconstruction tools and spatio-evolutionary models. Probability models were used to trace spatial and chronological origins of the primary tumor and metastases, chart their genetic drivers, and distinguish metastatic and non-metastatic subclones. Results In patient GP5, CDK12 inactivation was among the first mutations, leading to a PrCa tandem duplicator phenotype and initiating the cancer around age 50 , followed by rapid cancer evolution after age 57 , and metastasis around age 59, 5 years prior to prostatectomy. In patient GP12, accelerated cancer progression was detected after age 54 , and metastasis occurred around age 56,3 years prior to prostatectomy. Multiple metastasis-originating events were identified in each patient and tracked anatomically. Metastasis from prostate to lymph nodes occurred strictly ipsilaterally in all 12 detected events. In this pilot, metastatic subclone content analysis appears to substantially enhance the identification of key drivers. Evolutionary analysis' potential impact on therapy selection appears positive in these pilot cases.


[^0]Conclusions PrCa evolutionary analysis allows tracking of anatomic site of origin, timing of cancer origin and spread, and distinction of metastatic-capable from non-metastatic subclones. This enables better identification of actionable targets for therapy. If extended to larger cohorts, it appears likely that similar analyses could add substantial biological insight and clinically relevant value.
Keywords Prostate cancer, Cancer evolution, Cancer timing, Cancer anatomic origins, Spatiogenomic evolutionary tracing, Prostate cancer metastasis, Cancer phylogenetics, Cancer genomic drivers, Cancer heterogeneity

## Background

Prostate cancer ( PrCa ) in 2023 remains a major worldwide stress on patients, their families, and health systems, with 1.4 million newly diagnosed patients and 375,304 patient deaths in 2020 alone [1]. A diverse set of genomic mutation drivers of metastatic prostate cancer ( mPrCa ) has been reported [2-6]. Mutation heterogeneity in PrCa is likely a root cause of treatment failure [7, 8]. Somatic cancer evolution studies can unravel heterogeneity [9-15], but they have not been applied as a tool to improve outcomes in PrCa .
Unraveling heterogeneity of genomic changes in individual prostate cancers can only occur via evolutionary studies, where the combination of genomic changes present in a set of anatomically localized PrCa cells is compared systematically to genomic changes in a separate set of anatomically localized $\operatorname{PrCa}$ cells from the same patient. Collecting the necessary multiple anatomically and timeoriented samples of sufficient quality, obtaining sufficient genomic breadth and depth of coverage, and analyzing the resulting genomic data using appropriate methods are all major challenges to routine evolutionary analysis of primary and metastatic cancers. Recent work relating liquid biopsy-based evolutionary data $[13,16,17]$ is exciting and further work is needed to define the relationship between tissue and liquid-biopsy-based evolutionary changes in the context of clinical interventions.
Understanding the evolution of an individual PrCa through serial analysis in space and time may be more important than identifying actionable targets for therapy from single samples as in current practice. The most prominent recent example of this is our recent evolu-tion-based discovery of subclone eradication in a metastatic PrCa [13], with subsequent identification of a novel method to compare eradicated and resistant subclones to better resolve actionable targets for therapy [16]. Evolutionary context was similarly critical to identifying that most mPrCas have monoclonal origins [9, 11], that spread of primary prostate cancer to distant sites often occurs by separate subclones in space and time [11, 12], and that androgen receptor signaling gain occurs multiple times and through multiple mechanisms in the same patient's mPrCa under the selection pressure of androgen deprivation [7].

Histomorphologic multifocality, where physically separate foci of PrCa are detected in the same prostate, has long been known [18-20]. How often separate histomorphologic foci are also genomically independent clones of PrCA is not yet quantified, but recent studies based on whole genome, exome, FISH, copy number, and immunostaining studies suggest that independent clones of PrCa are likely to exist in many aging prostates [3, 12, 13, 21-31]. Evolutionary analysis of cancer foci in three dimensions in a series of cases will be required for definitive answers to this question.
Better understanding of cancer evolution has been critical to advancing biological understanding and therapeutic targeting in lung, pancreatic, and other cancers [32-35], but it should be emphasized that the total number of cases of PrCa and other cancers studied in detail in an evolutionary context remains small [36,37], likely due to the aforementioned difficulty of collecting and analyzing the right samples. Just as important, methods for analyzing evolution in cancer cell populations in individual patients are evolving themselves [38] and to date there are no generally accepted benchmarks for testing and proving the various current methods of evolutionary analysis [39]. The early phases of evolutionary analysis of cancer started with cytogenetic observations [40-43] and subsequently advanced through studies of single markers [44], general comparison of genomic content [7,9], to current methods which rely on multidimensional clustering on whole genome data often using Bayesian methods [13, 45-48], at times including single-cell sequencing [49]. The logical underpinnings of the evolutionary analysis of cancer are strong, since they are based on well-proven genetic principles [50], but much remains to be learned.
Relatively few studies have used multiregional genomic analysis to examine intraprostatic cancer evolution in relation to metastatic capability [10, 12, 13, 51-53], and to our knowledge, this is the first to sample all major cancer foci for analysis based on 3D histology, include multiple metastases in each patient, and use the most recent computational methods for evolutionary analysis. We attempted this in two men with highrisk prostate cancer with the aim of learning how such approaches might be combined with existing clinical
methods to potentially improve clinical outcome if applied in larger cohorts.

## Methods

## Patients and tissue dissection

Patients newly diagnosed with PrCa electing radical prostatectomy (RP) with $20 \%$ or greater preoperative risk of pelvic lymph node metastasis [54] were eligible for the study under Tampere University Hospital Ethics Committee approval R19074 (Table 1 and Additional file 1: Table S1) and provided written informed consent to participate in the study. Two patients (GP5 and GP12) found to have lymph node ( LN ) metastases based on postsurgical pathologic analysis were selected for this study. Extended pelvic lymph node dissection was performed in both cases, including lymph nodes dorsal and ventral to obturator vessels, and ventral to internal and external iliac vessels. GP5 was found to have a rare 1 mm positive lymph node in the anterior fibromuscular stroma, and $2 / 5$ left pelvic and $1 / 7$ right pelvic lymph nodes positive. GP12 was found to have $1 / 9$ left pelvic and $1 / 11$ right pelvic lymph nodes positive for mPrCa. Cancer invasion of seminal vesicle (SV) was detected in GP12 but not GP5. Pre- and post-surgical AJCC 7th ed. stages for GP5 and GP12 were T2bNxM0/pT3aN1M0 and T2cNxM0/ pT3bN1M0, respectively.

The entire tissues (prostate, seminal vesicles, and lymph nodes) removed at RP were sectioned fresh and fixed in PAXgene fixative and processed to preserve anatomic orientation, histology, DNA, and RNA as previously reported [55] (Additional file 1: Supplementary Results). Hematoxylin and eosin (H\&E) stained sections were whole-slide imaged (WSI) at $20 \times$ with a Nanozoomer S60 (Hamamatsu). Cancer regions of interest (ROI) and morphologic features in each block-face section WSI were annotated (Cytomine) (Additional file 1: Figs. S1 and S2). Cancer volumes of interest (VOI) for laser microdissection were constructed from $4 \mu \mathrm{~m} H \& E$ and interleaved $20 \mu \mathrm{~m}$ sections placed on nuclease and RNAse-free PET membrane FrameSlides (MicroDissect GmbH). From each laser-dissected sample, DNA was isolated using the PAXgene Tissue Allprep DNA method (Qiagen's PX10 Supplemental protocol). From GP5, 8 primary and 3 pelvic LN metastatic VOI were examined. From GP12, 6 primary, 2 SV invasive, and 3 pelvic LN metastatic VOI were examined. Examined VOI were selected to optimize anatomic dispersion, association with known morphologic risk factors (grade, margin and SV positivity), and research cost.

## DNA analysis and phylogenetic tree construction

Whole genome DNA sequencing was performed to a median read depth of 58 X for the normal reference

Table 1 Patient characteristics

| Feature | GP5 | GP12 |
| :---: | :---: | :---: |
| Prostate and urinary history in years prior to PrCa diagnostic biopsy | Age 55.8 symptoms of BPH and PSA 1.8, started on dutasteride. PSA dropped to 0.7 on dutasteride age 58.6, when dutasteride stopped. PSA then steadily rose from 2.8 at age 61, to 12 (percent free 13\%) at age 63.6 despite the course of finasteride, just before PrCa diagnostic biopsy | Age 56.2 PSA 2.3 (26\% free), Age 58.5 PSA 10 (19\% free) led to prostate biopsy |
| Urinary symptoms just prior to PrCa diagnostic biopsy | Urinary urgency and nocturia | Urinary frequency and decreased urinary stream |
| Plasma PSA just prior to PrCa diagnostic biopsy | $12 \mathrm{ng} / \mathrm{mL}$ | $10 \mathrm{ng} / \mathrm{mL}$ |
| Family history of cancer in first-degree relatives | History of lethal cancer in father and mother | History of cancer in father |
| Race/ancestry | White/Finnish | White/Finnish |
| AJCC 7th edition clinical stage (in use at study entry) | T2b NxM0 | T2c NxM0 |
| Biopsy Gleason Grade Group | 5 | 5 |
| Pathologic stage (after RP) | pT3aN1M0, stage group IVA | pT3bN1M0, stage group IVA |
| Radical prostatectomy Gleason Grade Group | 5 | 5 |
| Age at PrCa Diagnostic Biopsy/RP | 63.6/63.8 years | 58.5/58.7 years |
| Postoperative status (patient follow-up period: up to 6 years after RP) | Received EBRT to prostate fossa in the postoperative period. Put on leuprolide and bicalutamide. PSA nadir post RP $0.3 \mathrm{ng} / \mathrm{mL}$. PSA 6 years postop $0.11 \mathrm{ng} / \mathrm{mL}$. Status M0 at 6 years postop | Received EBRT to prostate fossa and pelvic lymph nodes in the postoperative period. Bone metastasis found 2 years post RP. PSA nadir post-RP $0.9 \mathrm{ng} /$ $\mathrm{mL},>1000 \mathrm{ng} / \mathrm{mL}$ at 6 years postop after bicalutamide, orchiectomy, cabazitaxel, carboplatin, and radium 223 treatments, shifted to palliative care with status M1c |

comparison blood leukocyte DNA samples taken just prior to prostatectomy, and 71X for primary tumor and metastatic samples using Illumina Novaseq 6000 machines with S4 reagents (Novogene). Sequenced reads were aligned to human genome reference hg38. Somatic copy number alterations (CNAs) were analyzed using Battenberg-hg38 [46], and structural variants (SVs) were analyzed with SvABA [56]. Subclonal reconstruction of cancer cell populations was done with DPClust [57]. Software and genome reference data sets for the project are listed in Additional file 1: Table S2. Aligned pairedend read variant calling followed GATK best-practices guidelines using GATK 4.1.8.1. Somatic variant calling accuracy was validated in comparison to the PCAWG pipeline (Additional file 1: Figs. S3 and S4, Supplementary Methods). A putative sequencing artifact cluster of undetermined origin was found to be present in both patients and all sequenced samples. The presence of a distinct mutational trinucleotide signature (Additional file 1: Fig. S5) in this cluster with a cosine similarity of $91.3 \%$ to SBS48 ("possible sequencing artifact"), along with low and inconsistent CCFs (0.02-0.17) for phylogeny reconstruction ruled out the possibility of cancer cell origin. This cluster was removed from the final results. An integrated list of variants identified in GP5 and GP12 is contained in Additional file 2 (Excel Doc A): Table S3. Structural variants identified in GP5 and GP12 are contained in Additional file 3 (Excel Doc B): Tables S4 and S5. The Battenberg purity and ploidy values of samples are contained in Additional file 3 (Excel Doc B): Table S6. Variants and copy number alterations matching recently described high-risk prostate cancer drivers [2, 4] (Additional file 3 (Excel Doc B): Table S7) were placed on the phylogenetic trees. Details of the bioinformatic analysis of the DNA sequencing data are provided in Additional file 1: Supplementary Methods. All subclonal cancer cell populations found in the sampled extraprostatic tissues (seminal vesicles and pelvic lymph nodes) were considered metastatic for the purposes of this analysis and their matching seeder cell populations inside the primary tumor were classified as having metastatic capability.

## Timing of cancer evolution using [ $C>T$ ]pG mutations and tandem duplications

In both patients, we considered the branch containing the largest number of $\mathrm{CpG}>\mathrm{TpG}$ mutations (COSMIC single base substitution signature 1, SBS1) [58] at the age of prostatectomy ( 63.8 for GP5 and 58.7 for GP12) as a molecular clock to estimate the calendar time of cancer progression in each patient. Similar to tumor evolution timing in the International Cancer Genome Consortium (ICGC) Pan-Cancer Analysis of Whole Genomes (PCAWG) project [6], we simulated an increase in the
mutational burden at 10,000 random time points following a uniform distribution up to 15 years before sampling (representing $\sim 25 \%$ of age at RP for both patients). The increase was modeled as a fivefold acceleration in the mutation burden after random time points, reflecting advanced stages of tumor evolution [6]. A fivefold increase matches the PCAWG estimate for prostate tumors, similar to most cancer types. The acceleration model considered that subclonal private mutations also occurred at fivefold acceleration, and time points that did not allow for the private mutations in each sample to occur at a fivefold accelerated rate were discarded. We derived chronological time estimates (and 95\% confidence intervals) by comparing SBS1 exposure in each subclone to the longest SBS1 branch as a time anchor for age at prostatectomy as well as introducing time points of interest where fivefold mutation accelerations occur.
GP5 tandem duplications (TDs) were assigned to evolutionary clusters based on SVs and cancer cell fractions (CCFs) of associated CNAs in the tumor samples using Euclidean distance. After this assignment, we tested for a correlation between CpG > TpG mutations and TDs. The TDs in subclones Ab and A were merged because of their closely matching CCFs in all but one sample (RApex), making the evolutionary assignment uncertain between the pair. Subclones Baa, Bc, Aba, and Aa were omitted from the analysis due to their low CCF (median less than 0.5 in all samples).

## Druggability analysis and mapping to current clinical guidelines

We analyzed the potential druggability of truncal and subclone-specific variants by querying their associated genes in the Drug-Gene Interaction Database (DGIdb) v4.2.0 [59] and related it to current clinical status and drug availability (Additional file 3 (Excel Doc B): Tables S8 and S9.

## Results

## Cancer evolutionary reconstruction in two patients with high-risk prostate cancer

We utilized whole genome sequencing data together with 3D anatomic and histomorphologic information from two men (GP5 and GP12) with high-risk PrCa undergoing radical prostatectomy to reconstruct the evolution of their cancers. A total of 22 sites were profiled from both patients, including multiple samples from the prostate, sites of spread to the SV, and pelvic LN metastases (Figs. 1 and 2, Additional file 1: Figs. S1, and S2). In patient GP5, the large primary tumor mass extended from the prostate posterior mid-apex to the apical surgical margin (Fig. 1a). In contrast, the intraprostatic distribution of GP12 PrCa differed greatly from GP5, with the

A


B


Left LNs


C

| Sample | Name |
| :---: | :---: |
| 1 | RApexCA |
| 2 | LApexCA |
| 3 | RCA1 |
| 4 | RCA2 |
| 5 | RCA3 |
| 6 | LCA1 |



| Sample | Name |
| :---: | :---: |
| 7 | LCA2 |
| 8 | LCA3 |
| 9 | RPelvicLNMet1 |
| 10 | LPelvicLNMet1 |
| 11 | LPelvicLNMet2 |

Fig. 1 Anatomic overview of GP5 whole genome sequenced samples. a Pseudo-3D anatomy of prostate sampling and pelvic lymph node (LN) metastasis regions of interest (ROI). Prostate regions containing cancer are in gray, and sampled volumes of interest (VOI) are the subset in darker gray. GP5 seminal vesicles contained no cancer. b Primary and metastatic cancer ROI outlined in black overlayed on H\&E stained face sections. c GP5 tumor samples analyzed. L/R, left or right; Apex, prostate apex; CA, cancer in primary organ; LN, lymph node; Met, metastasis. See also Additional file 1; Fig. S1. Samples with darker gray background color are from LN metastases


B



C

| Sample | Name |
| :---: | :---: |
| 1 | RMidApicalCA |
| 2 | LMidApicalCA |
| 3 | RMidBasaICA |
| 4 | LMidBasalCA |
| 5 | RApexCA |
| 6 | LApexCA |
| 7 | RSVBaseCA |
| 8 | LSVBaseCA |
| 9 | RPelvicLNMet1 |
| 10 | RPelvicLNMet2 |
| 11 | LPelvicLNMet |

tumor extending from posterior apex to posterior base and into both seminal vesicles, and only partially filled any given tissue block (Fig. 2a).
The subclonal composition of the samples from GP5 and GP12 was determined using Dirichlet process clustering of single nucleotide variants (SNVs) (Additional file 1: Supplementary Methods). The clustering revealed between one and seven prominently divergent cancer cell populations in each sampled region of the prostate tumor, as well as the monoclonal origin of the tumors in both patients (Figs. 3 and 4).
In GP5, tumor samples 6-LCA1 and 7-LCA2 contained the largest fraction of cancer cells harboring solely truncal (most recent common ancestor, MRCA) mutations, implicating the left posterior mid-apex region as the putative site of origin of the cancer (Fig. 3a). From this origin, the prostate carcinoma of GP5 diverged into two
major branches, A and B (Fig. 3b). Cluster B cells were most prominently present in the left side of the apex (sample 2-LApexCA), while reaching into the rightmost sampled region of the apex as well (1-RApexCA). Cluster A cells occupied the right side of the apical region of the prostate and reached more prominently into the sampled mid-section of the gland (samples 3-8). Strikingly, while cluster A cells represented the larger tumor mass in the sampled regions, only cluster B cells and their descendants were found in the LN metastases (Fig. 3a-c, Additional file 1: Fig. S6). Analysis of the CNA burden associated with metastasis and recurrence in prostate cancer showed significant separation between samples with large metastatic subclone fractions and the remaining samples (Additional file 1: Fig. S7), consistent with B-branch proven metastatic behavior and CNA burden studies [60].


Fig. 3 Evolutionary overview of GP5 whole genome sequenced samples. a Subclonal reconstruction of single nucleotide variants (SNVs) across the cancer samples (rows) into evolutionary clusters (colored segments in columns). Vertical lines on sample rows represent SNVs with the height of the lines corresponding to their cancer cell fractions (CCF) in the samples, mirrored on the negative side of the axis. Curve-fitted median cluster CCFs are shown on top of each cluster in every sample. The mutations in the most recent common ancestor (MRCA) truncal cluster T are present with a $\sim 1.0$ CCF in every sample, signifying that these mutations are present in every detected cancer cell. Subclonal SNVs are present with lower CCFs in the samples where the subclone is detected. Mutations detected only in a single sample (private mutations) appear in gray in the rightmost columns. The number of SNVs in each cluster is shown at the bottom of the columns. $\mathbf{b}$ Cladogram of the evolutionary clusters in GP5 cancer. The MRCA, represented by Cluster T, branched into two distinct lineages, a non-metastatic A-branch (green) and a metastatic B-branch (orange). c"Jawbreaker" plots combine evolutionary cluster information with the cluster CCFs to create a summary of the fractions of cancer cell populations present in each sampled location at the time of radical prostatectomy. Example jawbreaker plot at the top in gray describes how descending subclonal lineages are drawn on top of each other so that the surface (outermost layer) of the jawbreaker matches the fraction of cells belonging to the color-matching evolutionary clusters (see also Additional file 1: Fig. S6 for jawbreaker interpretation)


Fig. 4 Evolutionary overview of GP12 whole genome sequenced samples. a Dirichlet process clustering of GP12 single nucleotide variants (SNVs) across the cancer samples plotted as in Fig. 3a for GP5. Private mutations in samples RPelvicLNMet1 and RPelvicLNMet2 were further divided into two separate clusters. b Cladogram of the evolutionary clusters in GP1 2 cancer. The evolutionary tree has two non-metastatic branches, represented by clusters $A$ and $D$. The lineage of branch $C$ has undergone the most clonal expansions, putatively representing the most advanced form of the cancer. c Jawbreaker plots for GP12 samples

In GP12, the most ancestral form of the cancer was found in the left side of the prostate near the apex (sample 2-LMidApical), indicating this region as the origin of the cancer (Fig. 4a). From its origin, the tumor grew along the posterior prostate, towards the apex, base and both lateral sides of the prostate gland while accumulating unique genetic aberrations in each direction (clusters A-D). Interestingly, as the tumor grew over the midline of the gland, it separated into left and right-sided subpopulations (clusters Cba and Cbb) and this division was maintained in respective right and left-side lymph node metastases (Fig. 4a-c). The metastatic cancer cell populations found on the left side were, therefore, markedly different from the right side samples in terms of their subclonal composition. The dominant cancer cell populations in the metastatic samples consisted of cluster Cba 2 (olive green) cells on the right side and cluster Cbb (magenta) cells on the left side. The cancer cells that had metastasized to LNs were found in the basal region of the prostate and the SVs, with the exception of cluster B cells that were found only in the left apical region of the prostate and with a $4 \%$ CCF in the left pelvic LN. Overall,
cancer cells representing eight different evolutionary clusters were found in the metastatic samples.

## Evolutionary analysis as a lens for interpreting cancer driver heterogeneity

Copy number analysis with Battenberg software showed diploid genomes in all samples (Fig. 5a). A total of 35 putatively oncogenic somatic variants were mapped to the GP5 cancer evolutionary tree (Fig. 5b) [2, 4]. One of the most prominent oncogenic driver events was a truncal heterozygous CDK12 deletion coupled with stop gain (c.C1874G:p.S625X) on the second CDK12 allele, causing a tandem duplicator phenotype with a distinctive CNA profile with $907<5 \mathrm{Mb}$ duplicated regions throughout the genome (Additional file 1: Fig. S8) [61, 62]. While no TMPRSS2-ETS fusions that are typically associated with prostate cancer were found in GP5 PrCa, we discovered a 1.5 Mb chr21 chromatin region containing the TMPRSS2 gene fused into the $q$-arm of chr6. This aberration was found to be subclonal and only present in cluster Bb1, which is a late-emerging metastatic clone found in the left side LN metastasis. To our knowledge, this is the first

reported subclonal TMPRSS2 fusion [63]. The metastatic branch of GP5 acquired significantly more putative drivers (total 17) than the non-metastatic lineage (total 3). We identified two separate instances of gain of $A R$ and $A R$ enhancer regions in metastatic clusters Bb and Baa (Fig. 5b, Additional file 1: Fig. S8). Cluster Bb cells and their descendants were found with $\leq 12 \%$ CCFs in the primary tumor samples but were nearly clonal (CCF $\geq 86 \%$ ) in all metastases, highlighting their increased metastatic potential. Notably, if the main tumor mass in 4-RCA2/5RCA3 is declared the "index" lesion, this region contains only 16 of 35 ( $45.7 \%$ ) of the putatively oncogenic driver aberrations detected in the metastatic subclones identified in the apices (Supplementary Results). Integrative graphic overviews of copy number, structural variant, and driver changes were produced for all samples (Fig. 5a, b, Additional file 1: Figs. S8, S9).
The most prominent oncogenic somatic driver events in GP12 were homozygous losses of PTEN and CDKN1B, heterozygous BRCA2 loss with a frameshift on the second allele (c.3854dupA:p.N1287Kfs*1), and a TMPRSS2-ETV1 fusion. A total of 35 putatively pathogenic driver events were identified with the large majority being CNAs. A singular chromoplexy event created a rearrangement of chromosomes 7,10 , and 13 (Additional file 1: Fig. S9), resulting in a loss of both a copy of PTEN and BRCA2 in the MRCA cluster (Cluster T) of the evolutionary tree. Similar to GP5, selecting the two largest tumor foci (1-RMidApicalCA/2-LMidApicalCA) as the "index" lesion identifies only $16 / 36$
(44.4\%) driver changes identified in GP12 metastatic subclones (Additional file 1: Supplementary Results).

## Tracing the anatomic origins of cancer metastases using evolutionary status

The detailed anatomic annotations available for the samples from GP5 and GP12 allowed for the combination of this information with evolutionary status to reconstruct the paths of tumor propagation and spread in both patients.
In GP5, metastatic spread from prostate to pelvic lymph nodes occurred at least five separate times, by five evolutionarily distinct cancer cell populations represented by clusters Ba and Bb and their descendants (Fig. 3a). The cancer cell populations present in the left apical region of the prostate migrated to the two positive left pelvic lymph nodes, and at least once, spread occurred from the right apex to the right pelvic lymph node (Fig. 6a). The dominant population in the left side LNs (Bb1, yellow) was present in sample LCA1, indicating the left posterior region of the apex as a source of the spread. The dominant right-side LN metastatic cancer cell population consisted of cluster Bb2 cells that were found only in the right apical region of the primary tumor (sample 1-RApexCA). Notably, every descendant evolutionary cluster of the earliest cancer cells with proven metastatic capability also had a presence in the metastases (Fig. 3a, c), suggesting that cancer cell migration from the primary tumor to metastases is an ongoing process rather than a rare event.


Fig. 6 Mapping of the evolutionary clusters onto the anatomy of the prostate in GP5 and GP12. a In GP5, the anatomic mapping of non-metastatic and metastatic branches indicates multiple regions involved in metastatic spread. A star icon is shown at the approximate location of the most ancestral clones detected in the tumor, indicating the putative cancer anatomic origin. $\mathbf{b} \ln \mathrm{GP} 12$, the mapping of the evolutionary clusters onto the anatomy of the prostate shows the path of growth and evolutionary advancement from the posterior left side of the mid-apex (denoted by a star icon) towards the base and seminal vesicles (SV). "No entry" icons indicate evolutionary branches and directions of tumor growth that are not present in any of the sampled metastases (SV or lymph nodes (LN))

In GP12, metastatic spread was traced from multiple locations in the prostate base, apex, and seminal vesicles. The cancer cell populations in sampled region 7-RSVBase closely resembled the cancer cell populations found in the right-side lymph nodes (Fig. 4a, c), indicating it as the putative origin of the right-side metastases. Furthermore, sample 7-RSVBase was also the only known primary tumor location for cluster Cba2, which represented the dominant clone (CCF~90\%) in the right-side metastases. The closest resemblance of the cancer cell populations found in the left side lymph node metastasis was present in sample 8-LSVBase, strongly implicating it as the region of the left side metastatic spread. Sample 8-LSVBase was also the only known location of cluster Cbb2 which was found in the left side lymph node as a subclonal population ( $\mathrm{CCF}<5 \%$ ). In total, the metastatic spread of GP12 PrCa was traced back to a minimum of eight separate events representing the eight evolutionarily distinct cancer cell populations found in the LN metastases (Fig. 6b). Similar to GP5, all detectable descendant populations of the earliest metastatic populations were also present in the LN metastases and right- and left-sided metastatic subclones metastasized to ipsilateral lymph nodes.

## Chronological origins of primary cancer and cancer metastases

We used clock-like $\mathrm{CpG}>$ TpG mutations (COSMIC signature SBS1) [58] to track the cancers of both GP5 and GP12 chronologically (Fig. 7) within 95\% confidence intervals (CI) (Fig. 7a, c). The first detectable clonal expansion in GP5 occurred around the age of 57.7 (50.2-58.4, 95\% CI) (Fig. 7a, b). Thirteen more clonal expansions represented by the evolutionary clusters and signifying advancement of cancer [8] occurred in the following 5 years, estimated between ages 57.7 ( $50.2-58.4,95 \% \mathrm{CI}$ ) and 62.7 (62.5-63.0, $95 \% \mathrm{CI})$ before RP was performed at age 63.8. The most ancestral populations of cancer cells present in the LN metastases (clusters Ba and Bb ) emerged at the age of 59.8 (58.0-60.6 and 58.1-60.6 for Ba and $\mathrm{Bb}, 95 \% \mathrm{CI}$ ), 4 years prior to RP. The dominant metastatic cancer cell lineages (Bb1, $\sim 75 \%$ of left side and Bb2, $100 \%$ of right side LN, Fig. 3a, c) emerged at the age of 61.1 ( $60.4-61.8,95 \% \mathrm{CI}$ ) and 62.7 (62.5-63.0, $95 \% \mathrm{CI}$ ), respectively, 2.7 and 1.1 years prior to RP.
Analysis and evolutionary cluster assignment of the 746 TDs detected in the genome of GP5 that could be assigned to subclones (Fig. 3, Additional file 1: Fig. S10) showed a linear correlation with SBS1 mutations (Additional file 1: Fig. S10) at a rate of $\sim 2$ accumulated TDs per one SBS1 mutation ( $p$-value 0.00223 ). This observation allowed us to estimate the critical time point in the advancement of GP5 cancer when the TD phenotype became active due to biallelic inactivation of CDK12 [61, 62], placing it at approximately 50 years of age, after $\sim 75 \%$ of the MRCA mutations had occurred.

The chronological progression of GP12 PrCa analyzed using SBS1 mutations placed the earliest detectable branching event at age 50.9 (36.8-51.0, $95 \%$ CI). Rapid evolutionary progression of the cancer was observable after the age of 53.9 ( $47.5-54.7,95 \% \mathrm{CI}), 4.8$ years prior to RP at age 58.7 (Fig. 7c, d). Between ages 54 to 58.7, eleven detectable clonal expansions occurred as the carcinoma advanced. The most ancestral cancer cell population (cluster Cb ) found in the SV and LN metastases emerged at 56.3 ( $55.5-56.9,95 \% \mathrm{CI}$ ) years of age ( 2.4 years prior to RP), while the dominant metastatic populations of clusters Cba2 ( $\sim 85 \%$ of right side LN mets) and Cbb ( $\sim 40 \%$ of left side LN met) emerged 1.5 (56.8-57.7, 95\% CI) and 1.7 (56.6-57.5, $95 \% \mathrm{CI}$ ) years prior to RP, respectively.

Evolution in relation to clinical course and histomorphology In both cases, plasma total PSA and several simultaneously measured percent free PSA values were available from time prior to diagnosis of prostate cancer (Fig. 7b, d). In both GP5 and GP12, no significant difference in Gleason pattern or stromal appearance was identified histologically on visual analysis of $\mathrm{H} \& E$ stained sections in regions containing metastatic subclones versus those containing no metastatic subclones.

## Evolutionary analysis can be used as a tool for advancing precision medicine

We hypothesized that cancer evolutionary analyses such as those shown here for GP5 and GP12 could be used to inform and improve patient treatment. We analyzed the potential druggability of somatic tumor variants identified in both patients in the context of somatic cancer evolutionary status, focusing on exonic and splice site variants with predicted protein-altering effects, copy number gains, and homozygous losses observed in the DNA (with the exception of TP53, for which we considered loss of heterozygosity to be potentially druggable) (Additional file 3 (Excel Doc B): Tables S8 and S9, Additional file 1: Supplementary Results). For GP5, CDK12 inactivation and gains of AKT1, GSK3B, PIK3CA, CCND1, and MDM2 were identified as the top truncal druggable targets that would be most likely to obtain a durable response due to their presence in all cancer cells. In GP12, top truncal druggable targets were the inactivation of BRCA2, and PTEN. Several druggable subclonal somatic cancer variants were further identified in both patients, such as $A R, E S R 1, E G F R, K R A S$, and $M E T$ in GP5, and HRAS, TP53, KRAS, BRAF, and AKT1 in GP12. The subclonal evolutionary status of these variants makes them less likely to obtain a durable response if targeted exclusively, demonstrating the utility of evolutionary analysis in prioritizing druggable targets and designing combination treatments.

A

|  | Median <br> age | $95 \%$ Conf. <br> interval | CpG $>$ TpG | TD |
| :---: | :---: | :---: | :---: | :---: |
| T | 57.7 | $[50.2-58.4]$ | 315 | 152 |
| A | 58.6 | $[53.8-59.4]$ | 22 | 31 |
| B | 59.3 | $[56.2-60.1]$ | 37 | 76 |
| Ab | 59.3 | $[56.3-60.2]$ | 16 | 50 |
| Abb | 59.4 | $[56.5-60.2]$ | 1 | 7 |
| Ba | 59.8 | $[58.0-60.6]$ | 11 | 37 |
| Bb | 59.8 | $[58.1-60.6]$ | 12 | 63 |
| Aa | 59.9 | $[58.6-60.7]$ | 30 | 26 |
| Baa | 60.1 | $[59.1-60.9]$ | 8 | 38 |
| Abba | 60.5 | $[59.6-61.2]$ | 26 | 27 |
| BC | 61.0 | $[60.2-61.7]$ | 39 | 12 |
| Bb1 | 61.1 | $[60.4-61.8]$ | 30 | 81 |
| Aba | 61.2 | $[60.5-61.8]$ | 43 | 26 |
| Bb2 | 62.7 | $[62.5-63.0]$ | 68 | 120 |




Fig. 7 Chronological progress of prostate carcinogenesis. a, c Analysis of single base substitution (COSMIC SBS) signature 1 mutations ( $C p G>T p G$ ) shows the evolutionary progression of the cancer in calendar time preceding radical prostatectomy (RP). The median age estimates and 95\% confidence intervals (square brackets) of each cluster from simulations starting at random time points up to 15 years before RP are shown. For GP5, the number of tandem duplications (TDs) caused by CDK12 inactivation detected in each evolutionary cluster is shown in the table as their correlation with SBS1 mutations was used to estimate the start of the TD phenotype. $\mathbf{b}, \mathbf{d}$ Age-referenced cancer subclone cladogram for each patient. The nodes in the trees are shown at the age where a single progenitor cell (most recent common ancestor, MRCA) of the evolutionary cluster emerged and subsequently underwent clonal expansion. The gray line connecting a leaf node to RP shows the longest path (LP) of signature 1 mutations that were used in the timing of the emergence of the evolutionary clusters. Timeline markers for the emergence of the first evolutionary clone and the dominant clone detected in the metastasis are noted as "1st met" and "adv. met". On the right to the cladogram, plasma total prostate specific antigen (PSA) levels are placed on the timeline in dark gray, together with corresponding percent free PSA values in light gray when available. GP5 received dutasteride and finasteride for symptoms of benign prostatic hyperplasia during the time periods marked with pink and orange boxes

## Druggability analysis

Druggable targets with available drugs and clinical trial evidence of potential value to patients exist in both cases, but many are not yet part of standard care or available in specific trials in Finland (Additional file 3 (Excel Doc B): Tables S8 and S9).

## Discussion

We traced the anatomic and chronologic origins of primary tumor and metastases in two men. We determined that PrCa cells escaped from the prostate of GP5 and GP12 at least 5 and 8 times respectively, in each instance traveling ipsilaterally from the prostate to lymph nodes.

We also show that intraprostatically, metastatic subclones can migrate across the midline. Multiple instances of cell transit from the prostate to lymph nodes confirm previous findings $[11,12]$ and resonate with studies showing that selected patients can benefit from removal of the prostate in locally advanced [64] or even metastatic [65] PrCa , because more prostate dwell-time appears to mean more instances of metastasis.
The results allow the "curative time window" between the first $\operatorname{PrCa}$ detectability and first metastasis formation to be addressed. Based on the number of accumulated $\mathrm{mPrCa}-$ associated driver mutations, the approximate period that aggressive, but solely nonmetastatic PrCa existed in GP5 was between ages 50.5 and 59.8, and in GP12, between ages 50.9 and 56.3. Therefore, the window for curative RP may have closed approximately 4 and 3 years prior to RP surgery for GP5 and GP12, respectively. The combined timing and evolutionary analysis (Fig. 7b, d) show that if genetic sampling of the cancerous cells would be possible at the onset of the symptoms that prompted the first visits to the clinic, before metastatic potential was reached, the tumor cells would already be clearly recognizable as malignant based on the existing oncogenic driver events.
Extraprostatic spread in both cases occurred solely from the apex, base, or seminal vesicles. If this tendency holds in larger cohorts, staging should become more focused on these anatomic sites. Consistent with this, a "wall" of nonmetastatic tumor existed at mid-prostate (Fig. 1), where the tumor originated in GP5, while GP5's metastatic tumor evolved as it migrated to and spread from the prostate apex.
In GP5 and GP12, two patients who presented with prostate cancer in a high-risk category who elected to undergo a robotic prostatectomy, cancer sites harboring solely nonmetastatic subclones are large but contain only $45.7 \%$ and $44.4 \%$ of the oncogenic drivers detected in metastatic subclones, suggesting that dangerous lesions are not necessarily larger and cannot be identified based on histology alone, as witnessed in Haffner et al. [10]. Evolutionary studies could help refine how index lesions are defined. This study did not include an analysis of epigenetic and transcriptomic changes at the bulk or singlecell level, and these will likely further increase the value of gradually reengineering PrCa practice to include evolution as a key element.
Taken together, these results suggest that with similarly detailed analysis of a larger cohort of patients, it may be possible to distinguish metastatic-capable from meta-static-incapable subclones in previously unseen primary tumor biopsies based on evolutionary status (truncal/ subclonal), number and combination of driver events, and anatomic location.

## Conclusions

Here we show that PrCa evolutionary analysis allows tracking of anatomic site of origin, timing of cancer origin and spread, and distinction of metastatic-capable from non-metastatic subclones. We therefore provide evidence that cancer somatic evolutionary context is fundamentally important to establishing a framework for effective personalized medicine in PrCa. Our analysis suggests that key aspects of current prostate cancer practice can be improved if similar detailed studies are performed in larger cohorts. Well-established oncogenic driver events in PrCa have a roughly $5 \%$ mean frequency in tested cohorts. An evolution-aware longitudinal clinical trial including for example 500 men in intermediate or high preoperative risk categories would enable trial-based treatment designed to formally test the value of such an approach. Taken together with our recent evolutionary-analysis-based discovery that solid tumor subclones can be eradicated [13], and that comparison of eradicated and resistant subclones can guide therapy [16], we believe the case for embarking on a deliberate evolution-based transformation of PrCa care is compelling.

| Abbreviations |  |
| :--- | :--- |
| AJCC | American Joint Committee on Cancer (staging system) |
| AR | Androgen receptor |
| BPH | Benign prostatic hyperplasia |
| CCF | Cancer cell fraction |
| Cl | Confidence interval |
| CNA | Copy number alteration |
| DGIdb | Drug-gene interaction database |
| EBRT | External beam radiation therapy |
| FISH | Fluorescence In-Situ Hybridization |
| GP | Geoprostate |
| FusionGDB | Fusion gene annotation database |
| H\&E | Hematoxylin and eosin |
| HRR | Homologous recombination repair (pathway) |
| LN | Lymph node |
| mCRPC | Metastatic castrate-resistant prostate cancer |
| mPrCa | Metastatic prostate cancer (includes both mCRPCs and meta- |
|  | static hormone-sensitive metastatic prostate cancer) |
| MRCA | Most recent common ancestor |
| MRI | Magnetic resonance imaging |
| PARP | Poly ADP-ribose polymerase (protein family) |
| PCAWG | Pan-cancer analysis of whole genomes (project) |
| PET | Positron emission tomography |
| PIN | Prostatic Intraepithelial neoplasia |
| postop | Postoperative |
| PrCa | Prostate cancer |
| PSA | Prostate-specific antigen |
| ROI | Region of interest |
| RP | Radical prostatectomy |
| SBS | Single base substitution (signature) |
| SNV | Single nucleotide variant |
| SV | Structural variant |
| SV | Seminal vesicle |
| TD | Tandem duplication |
| VOI | Volume of interest |
| WGS | Whole genome sequencing |
| WSI | Whole-slide imaging |

## Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s13073-023-01242-y.

Additional file 1: Supplementary Material PDF including supplementary material index, supplementary tables 1 and 2 , supplementary figures, supplementary methods, and supplementary references.
Additional file 2: Supplementary table S3 (Excel Doc A) Annotated GP5 and GP12 GATK4.1.8.1 Variant list.

Additional file 3: Supplementary tables S4-S9 (Excel Doc B).

## Acknowledgements

We thank the patients participating in the study and their families. We acknowledge technical support from Marja Pirinen, Päivi Martikainen, Hanna Selin, Paula Kosonen, Maria Pekki, Annamari Aitolahti, Anni Mäkinen, Teppo Haapaniemi, Tommi Pajala, likka Sainio, Timo Talvitie, Jan Silander, Jonas Demeulemeester, and Maxime Tarabichi.

## Authors' contributions

All authors read and approved the final manuscript. G. Steven Bova had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Bova, Van Loo, Wedge, Visakorpi, Nykter. Acquisition of data: Bova, Högnäs, Koskenalho, Tolonen, Kujala, Riikonen, Tammela, Murtola, Rinta-Kiikka, Jasu, Rauhala, Kesäniemi, Nikupaavola. Analysis and interpretation of data: Nurminen Taavitsainen, Jaatinen, Lesluyes, Ansari-Pour, Tolonen, Haase, Kankainen, RintaKiikka, Riikonen, Nykter, Wedge, Van Loo, Bova. Drafting of the manuscript: Bova Nurminen, Taavitsainen, Koskenalho, Jaatinen, Högnäs, Kankainen, Tammela. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Taavitsainen, Lesluyes, Ansari-Pour, Jaatinen, Nurminen, Nykter, Wedge, Van Loo. Obtaining funding: Bova, Nykter, Visakorpi, Van Loo, Wedge. Administrative, technical, or material support: Bova, Koskenalho, Högnäs, Tolonen. Supervision: Bova, Van Loo, Wedge, Nykter.

## Funding

Open access funding provided by Tampere University (including Tampere University Hospital). Financial support to G. Steven Bova for the study includes the following: Academy of Finland (2011 to 2020), Cancer Society of Finland (2013 to present), Sigrid Juselius Foundation (2016 to present), and CSC-IT Center for Science, Finland (2016 to present). Financial support to Naser Ansari-Pour for computational aspects of this research was partly supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Sinja Taavitsainen and Antti Kaipia were partly supported by the Finnish Cultural Foundation. Antti Kaipia was partly supported by the Cancer Society of Finland. This work was supported in part by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2008), the UK Medical Research Council (CC2008), and the Wellcome Trust (CC2008). For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. PVL is a Winton Group Leader in recognition of the Winton Charitable Foundation's support towards the establishment of The Francis Crick Institute. P.V.L. is a CPRIT Scholar in Cancer Research and acknowledges CPRIT grant support (RR210006). This work was supported in part by the Academy of Finland Center of Excellence program (project no. 312043 for MN)

## Availability of data and materials

Whole genome sequence data for the study are available in the European Genome-Phenome Archive (EGA Accession number EGAD50000000005) [66]. Other supporting data is contained in Supplementary Material.

## Declarations

## Ethics approval and consent to participate

The research conforms to the principles of the Helsinki Declaration. Patients provided informed consent for the study under Tampere University Hospital Ethics Committee approval R19074.

## Consent for publication

Consent was obtained from the patients to publish clinically and scientifically relevant patient-related information included in the study. To reduce re-identification risk, some of the reported clinical data has been reduced in specificity.

## Competing interests

G. Steven Bova certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Naser Ansari-Pour, Kerstin Haase, Gunilla Högnäs, Serafiina Jaatinen, Juho Jasu, Antti Kaipia, Matti Kankainen, Antti Koskenalho, Jenni Kesäniemi, Tiia Nikupaavola, Paula Kujala, Tom Lesluyes, Anssi Nurminen, Hanna Rauhala, Jarno Riikonen, Irina Rinta-Kiikka, Sinja Taavitsainen, Teemu Tolonen, Peter Van Loo, Tapio Visakorpi, and David Wedge have no conflict of interest disclosures. Teemu J. Murtola has received honoraria from Astellas, Janssen, Novartis, and Sanofi; has received travel and accommodation expenses from Sanofi and Pfizer; reports patents, royalties, and other intellectual property from Arocell; reports stock and other ownership interests in Arocell; and has received research funding from Arocell. Teuvo Tammela has received research funding from Finnish Cancer Society and Sigrid Juselius Foundation and has been an investigator in studies sponsored by Bayer, Astellas, Orion Pharma, and Pfizer. Bova and Nykter report intellectual property for Differential Subclone Eradication and Resistance (DSER) analysis [16]. Bova also reports speaker's fees from Brupbacher Foundation, Sanofi Aventis, and Astellas Pharma.

## Author details

${ }^{1}$ Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014 Tampere, Finland. ${ }^{2}$ The Francis Crick Institute, London NW1 1AT, UK. ${ }^{3}$ MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. ${ }^{4}$ Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland. ${ }^{5}$ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, ECRC Experimental and Clinical Research Center, Berlin, Germany. ${ }^{6}$ Institute for Molecular Medicine Finland, University of Helsinki, Tukholmankatu 8, Helsinki 00290, Finland. ${ }^{7}$ Imaging Centre, Department of Radiology, Tampere University Hospital, Tampere, Finland. ${ }^{8}$ Department of Urology, TAYS Cancer Center, Tampere University Hospital, Tampere, Finland. ${ }^{9}$ Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK. ${ }^{10}$ Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ${ }^{11}$ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Received: 13 April 2023 Accepted: 2 October 2023
Published online: 12 October 2023

## References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
2. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-43.
3. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666-77.
4. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28.
5. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50(5):682-92.
6. Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock $D$, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578(7793):122-8.
7. Bova GS, Kallio HML, Annala M, Kivinummi K, Högnäs G, Häyrynen S, et al. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud. 2016;2(3): a000752.
8. Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell. 2018;173(4):1003-1013.e15.
9. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559-65.
10. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918-22.
11. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil $E$, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353-7.
12. Hong MKH, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015;6:6605.
13. Woodcock DJ, Riabchenko E, Taavitsainen S, Kankainen M, Gundem G, Brewer DS, et al. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11(1):5070
14. Swanton C. Take lessons from cancer evolution to the clinic. Nature 2020;581 (7809):382-3.
15. Tarabichi M, Salcedo A, Deshwar AG, Ni Leathlobhair M, Wintersinger J, Wedge DC, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods. 2021;18(2):144-55.
16. Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodríguez-Martín B, et al. Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity. Cancer Res. 2021;81(19):4901-9.
17. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022;608(7921):199-208.
18. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol. 1991;146(4):1069-76.
19. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994;43(1):60-6.
20. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Part 2):1709-13.
21. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67(17):7991-5.
22. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;63(2):347-53.
23. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015;47(4):367-72.
24. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47(7):736-45.
25. Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, et al. Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. Eur Urol. 2017;71 (2):183-92.
26. VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, et al. Genomic heterogeneity within individual prostate cancer foc impacts predictive biomarkers of targeted therapy. Eur Urol Focus. 2019;5(3):416-24.
27. Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur Urol. 2019;75(3):498-505.
28. Wu B, Lu X, Shen H, Yuan X, Wang X, Yin N, et al. Intratumoral heterogeneity and genetic characteristics of prostate cancer. Int J Cancer. 2020;146(12):3369-78.
29. Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, et al. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight. 2022;7(4): e155309.
30. Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, et al. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022;257(3):274-84.
31. Kristiansen A, Bergström R, Delahunt B, Samaratunga H, Guðjónsdóttir J, Grönberg H , et al. Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate. 2019;79(8):920-8.
32. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346(6206):251-6.
33. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-7.
34. O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390-403.
35. Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-893.e13.
36. Erickson A, Hayes A, Rajakumar T, Verrill C, Bryant RJ, Hamdy FC, et al. A systematic review of prostate cancer heterogeneity: understanding the clonal ancestry of multifocal disease. Eur Urol Oncol. 2021;4(3):358-69.
37. Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79-92.
38. Jolly C, Van Loo P. Timing somatic events in the evolution of cancer. Genome Biol. 2018;19. Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6057033/. [cited 2020 Feb 14].
39. Salcedo A, Tarabichi M, Espiritu SMG, Deshwar AG, David M, Wilson NM, et al. A community effort to create standards for evaluating tumor subclonal reconstruction. Nat Biotechnol. 2020;38(1):97-107.
40. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-8.
41. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci. 2008;121 Suppl 1:1-84.
42. Tsao JL, Zhang J, Salovaara R, Li ZH, Järvinen HJ, Mecklin JP, et al. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998;153(4):1189-200.
43. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, Schäffer AA. Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol. 1999;6(1):37-51.
44. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995;1(10):1111-8.
45. Navin NE, Hicks J. Tracing the tumor lineage. Mol Oncol. 2010;4(3):267-83.
46. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994-1007.
47. Deshwar AG, Vembu S, Yung CK, Jang GH, Stein L, Morris Q. PhyloWGS: reconstructing subclonal composition and evolution from wholegenome sequencing of tumors. Genome Biol. 2015;16(1):35.
48. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11(4):396-8.
49. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90-4.
50. Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. EMBO J. 2021;40(18): e108389.
51. VanderWeele DJ, Brown CD, Taxy JB, Gillard M, Hatcher DM, Tom WR, et al. Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci. 2014;105(8):1079-85.
52. Lindberg J, Kristiansen A, Wiklund P, Grönberg H, Egevad L. Tracking the origin of metastatic prostate cancer. Eur Urol. 2015;67(5):819-22.
53. Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, et al. Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. Int J Cancer. Available from: https://onlinelibrary. wiley.com/doi/abs/10.1002/ijc.34226. [cited 2022 Oct 17].
54. Prostate Cancer Nomograms: Post-Radical Prostatectomy | Memorial Sloan Kettering Cancer Center. Available from: https://www.mskcc.org/ nomograms/prostate/post_op. [cited 2020 Apr 29].
55. Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, et al. Feasibility of prostate PAXgene fixation for molecular research and diagnostic surgical pathology: comparison of matched fresh frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018;42(1):103-15.
56. Wala JA, Bandopadhayay P, Greenwald NF, O'Rourke R, Sharpe T, Stewart C, et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018;28(4):581-91.
57. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
58. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94-101.
59. Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the Drug-Gene Interaction Database (DGldb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021;49(D1):D1144-51.
60. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014;111(30):11139-44.
61. Wu YM, Cieslik M, Lonigro RJ, Pankaj V, Reimers MA, Xuhong C, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173(7):1770-1782.e14.
62. Antonarakis ES, Velho PI, Fu W, Wang H, Agarwal N, Santos VS, et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precision Oncol. 2020; Available from: https://ascopubs.org/doi/pdf/10.1200/PO.19.00399. [cited 2020 May 4].
63. Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021;184(8):2239-2254.e39.
64. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243-62.
65. Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, et al. Radical prostatectomy improves survival in selected metastatic prostate cancer patients: a North American population-based study. Int J Urol. 2021. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/iju. 14586. [cited 2021 Jun 5].
66. European Genome-Phenome Archive [Internet]. Cancer origin tracing and timing in two high risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Whole Genome Sequence Data. Available from: https://ega-archive.org/studies/EGAD5 0000000005.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100 M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
BMC


[^0]:    *Correspondence:
    G. Steven Bova
    steve.bova@tuni.fi
    Full list of author information is available at the end of the article

